Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US

Date

14 Sep 2024

Session

Poster session 10

Topics

Genetic and Genomic Testing

Tumour Site

Breast Cancer;  Non-Small Cell Lung Cancer;  Prostate Cancer;  Pancreatic Adenocarcinoma;  Colon and Rectal Cancer

Presenters

Chadi Hage Chehade

Citation

Annals of Oncology (2024) 35 (suppl_2): S937-S961. 10.1016/annonc/annonc1606

Authors

C. Hage Chehade1, A. Narang1, Y. JUNG JO2, Z.I. Ozay1, G. Gebrael1, N. Tripathi1, B. Chigarira1, A. Srivastava1, R. Ji1, D. Garg1, V. Mathew Thomas1, H. Li3, S. Roy4, B.L. Maughan1, U. Swami1, N. Agarwal1

Author affiliations

  • 1 Division Of Medical Oncology, Department Of Internal Medicine, University of Utah Health - Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 2 Division Of Biostatistics, Department Of Population Health Sciences, School Of Medicine, University of Utah Health - Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 3 Division Of Medical Oncology, Department Of Internal Medicine, University of Kansas Cancer Center, 84112 - Salt Lake City/US
  • 4 Radiation Oncology Department, Rush University Medical Center - Woman's Board Center for Radiation Therapy, 60612 - Chicago/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1580P

Background

In the US, 5 most common advanced/metastatic (met/adv) solid tumors are metastatic non-small cell lung cancer (mNSCLC), metastatic breast cancer (mBC), metastatic prostate cancer (mPC), metastatic colorectal cancer (mCRC), and metastatic pancreatic cancer (mPanC). Current guidelines recommend NGS testing for pts with these malignancies due to approved life-prolonging therapies for pts with driver mutations. However, large cohort studies evaluating disparities in NGS testing have not been reported. Herein, we investigated the effect of SDOH on disparities in NGS testing in these tumors.

Methods

In this IRB-approved retrospective study, pt-level data were extracted from the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database. Inclusion criteria: pts diagnosed with mNSCLC, mBC, mPC, mCRC, and mPanC between 2018 and 2022, with available treatment information. Disparities in the rates of NGS testing were assessed by socioeconomic status (SES), race-ethnicity (R/E), region, and insurance were assessed using Fine and Grey’s modified Cox proportional hazard model with NGS testing as the event of interest and death as a competing risk. Different baseline hazards by the year of met/adv diagnosis were assumed. Complete case analysis was performed for each analysis. All analysis was done using R v.4.2.3.

Results

The analytic cohort included 21964, 9872, 3560, 10942, and 4945 pts with mNSCLC, mBC, mPC, mCRC, and mPanC, respectively. Pts with lower SES were less likely to receive NGS testing. Results are summarized in the table. Further disparities in NGS testing by R/E, insurance type, and region will be presented in the meeting. Impact of SES on NGS testing (HR>1 indicates more NGS testing). Table: 1580P

Cancer SES mNSCLCn=21964 mBCn=9872 mPCn=3560 mCRCn=10942 mPanCn=4945
5 –High (reference) HR (95% CI)
- - - - -
4 0.97 (0.93 – 1.01) p=0.13 1.02 (0.94 – 1.11) p=0.58 0.99 (0.89 – 1.10) p=0.80 1.05 (0.99 – 1.11) p=0.11 1.05 (0.96 – 1.14) p=0.28
3 0.91 (0.87 – 0.95) p

Conclusions

Our findings suggest that pts with lower SES were less likely to get NGS testing, potentially reducing access to life-prolonging therapies. These results highlight the need for policies to mitigate this disparity.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S. Roy: Financial Interests, Research Grant: Prostate Cancer Foundation, Swim Across America Foundation; Financial Interests, Speaker, Consultant, Advisor: Varian Medical Systems. B.L. Maughan: Financial Interests, Speaker, Consultant, Advisor: AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, Bristol Myers Squibb, Clovis, Tempus, Merck, Exelixis, Bayer Oncology, Lilly, Sanofi, Telix, Xencor, NCCN, Peloton Therapeutics; Financial Interests, Research Funding: Exelixis, Bavarian-Nordic, Clovis, Bristol Myers Squibb. U. Swami: Financial Interests, Personal, Writing Engagement: Astellas; Financial Interests, Personal, Advisory Board: SeaGen, Exelixis, AstraZeneca, Adaptimmune, Gilead, Imvax, Pfizer, Sanofi; Financial Interests, Institutional, Research Grant: Janssen, Exelixis; Financial Interests, Institutional, Local PI: Astellas/Seattle Genetics. N. Agarwal: Financial Interests, Personal, Invited Speaker, Invited speaker: Medscape; Financial Interests, Personal, Invited Speaker, Invited Speaker: Onclive, Research to Practice, Clinical Care Options; Financial Interests, Institutional, Other, I serve in the leadership of my cancer center (Huntsman Cancer Institute, University of Utah. Salt Lake City, UT, USA). There are multiple research projects sponsored by these companies which pay money to my institution: Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, Telix, Tracon.; Financial Interests, Steering Committee Member, I am involved in the steering committee of the trials sponsored by these pharmas with no personal honorarium: AstraZeneca, Calithera, Crispr, Eli Lilly, Exelixis, Immunomedics, Merck, Pfizer,; Financial Interests, Steering Committee Member, I am involved in the steering committee of the trials sponsored by these pharma companies with no personal honorarium: Merck, Nektar, New Link Genetics, Oric, Pfizer, Prometheus, Rexahn, Takeda, Telix,Tracon; Financial Interests, Trial Chair, One of the two co-chairs of the clinical trials sponsored by these pharma companies. I have not received any honorarium for these roles.: Pfizer, Exelixis, Janssen, Telix.; Non-Financial Interests, Member, I am a long-standing member of ASCO and a volunteer. I was awarded the fellow of ASCO in 2023. I also act as the editor of the ASCO Daily News as a volunteer.: Amercian Society of Clinical Oncology; Non-Financial Interests, Member, I am a member of this NCI and NCTN-sponsored cooperative clinical trial network group: SWOG; Non-Financial Interests, Member, I am a member of these professional organizations.: AACR, AUA, PCF. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.